Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.30 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.30 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL900904 | 0.84 | DRD1 (0.35) | — | |
| SCHEMBL25185702 | 0.79 | CSNK2A1 (0.30) | — | |
| SCHEMBL1063853 | 0.77 | — | — | |
| SCHEMBL900073 | 0.77 | — | — | |
| SCHEMBL1067798 | 0.75 | — | — | |
| SCHEMBL1068228 | 0.75 | DRD1 (0.31) | ALDH1A1 | |
| SCHEMBL1065553 | 0.75 | — | — | |
| SCHEMBL1067923 | 0.72 | — | — | |
| SCHEMBL1068130 | 0.72 | MEN1 (0.31) | MEN1LMNAMAPTKMT2ANPSR1 | |
| SCHEMBL28520506 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020191501-A1 | METHODS AND USES OF BEMITHYL AND DERIVATIVES FOR TREATING LUNG DISEASE, FATTY LIVER DISEASE, AND KIDNEY DISORDERS | ALGERNON PHARMACEUTICALS INC. (CA) | 2020-10-01 | — | — | WO | disclosed |
| EP-3080119-B1 | TETRAHYDROIMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2020-07-08 | — | — | EP | disclosed |
| EP-3080128-B1 | IMIDAZOPYRIDAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2020-06-24 | — | — | EP | disclosed |
| EP-3080127-B1 | IMIDAZOPYRIMIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2020-06-24 | — | — | EP | disclosed |
| EP-3080123-B1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2020-06-17 | — | — | EP | disclosed |
| EP-3080129-B1 | IMIDAZOTRIAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2020-06-03 | — | — | EP | disclosed |
| EP-3080112-B1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2020-06-03 | — | — | EP | disclosed |
| EP-3080117-B1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2020-06-03 | — | — | EP | disclosed |
| EP-3080130-B1 | TRIAZOLOPYRIDAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2020-06-03 | — | — | EP | disclosed |
| EP-3303337-B1 | FUSED TRICYCLIC IMIDAZO PYRAZINES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2020-05-27 | — | — | EP | disclosed |
| WO-2011069916-A1 | TRIAZOLE COMPOUNDS, USE THEREOF AS A FUNGICIDE, AND AGENTS COMPRISING SAME | BASF SE (DE) | 2011-06-16 | — | — | WO | disclosed |
| CN-101952279-A | Azolylmethyloxiranes, use thereof and agents containing the same | BASF SE | 2011-01-19 | — | — | CN | disclosed |
| CN-101945580-A | Azolylmethyloxiranes, use thereof and compositions comprising them | BASF SE | 2011-01-12 | — | — | CN | disclosed |
| WO-2010149758-A1 | ANTIFUNGAL 1, 2, 4-TRIAZOLYL DERIVATIVES | BASF SE (DE) | 2010-12-29 | — | — | WO | disclosed |
| US-20100317515-A1 | Azolylmethyloxiranes, use Thereof and Agents Containing the Same | BASF SE (DE) | 2010-12-16 | — | — | US | disclosed |
| US-20100311581-A1 | Azolylmethyloxiranes, use Thereof and Agents Containing the Same | BASF SE (DE) | 2010-12-09 | — | — | US | disclosed |
| CN-101902914-A | Azolylmethyloxiranes, use thereof and compositions comprising same | BASF SE | 2010-12-01 | — | — | CN | disclosed |
| US-20100273651-A1 | Azolylmethyloxiranes, use Thereof and Agents Containing the Same | BASF SE (DE) | 2010-10-28 | — | — | US | disclosed |
| EP-2235005-A2 | AZOLYLMETHYLOXIRANES, USE THEREOF AND AGENTS CONTAINING THE SAME | BASF SE (DE) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009077500-A2 | AZOLYLMETHYLOXIRANES, USE THEREOF AND AGENTS CONTAINING THE SAME | BASF SE (DE) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317515-A1 | Azolylmethyloxiranes, use Thereof and Agents Containing the Same | XDH, NOX5, TET1 | ALDH1A1 20/4885MEN1 1724/4885LMNA 4209/4885 |
| US-20100273651-A1 | Azolylmethyloxiranes, use Thereof and Agents Containing the Same | XDH, SQOR, NOX5 | ALDH1A1 14/4885MEN1 1585/4885LMNA 4264/4885 |
| US-20100311581-A1 | Azolylmethyloxiranes, use Thereof and Agents Containing the Same | XDH, DAO, DHODH | ALDH1A1 25/4885MEN1 1626/4885LMNA 4292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.